Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  03/05/2004
 
Trade Name:  Arava
 
Generic Name or Proper Name (*):  leflunomide
 
Indications Studied:  Polyarticular Juvenile Rheumatoid Arthritis
 
Label Changes Summary:  Safety and efficacy in pediatric patients with polyarticular JRA have not been fully evaluated 94 patients with polyarticular JRA were studied in a double-blind active controlled trial (1:1 randomization); approximately 68% of pediatric patients receiving Arava versus 89% receiving active comparator demonstrated improvement on the primary endpoint by week 16 Pediatric patients with a body weight d 40 kg have a reduced clearance relative to adult rheumatoid arthritis patients Information on PK of M1, the active metabolite responsible for in vivo activity in children 3-17 years old Most common adverse events in 74 polyarticular JRA patients 3-17 years old included abdominal pain, diarrhea, nausea, vomiting, oral ulcers, upper respiratory tract infections, alopecia, rash, headache, and dizziness 14 of the 74 patients experienced ALT and/or AST elevations; 5/14 were between 3 and 8 fold the upper limit of normal
 
Product Labeling:  Labeling  Opens a new window
 
BPCA(B) and PREA(P):  B, P
 
Sponsor:  Aventis
 
Pediatric Exclusivity Granted Date:  11/10/2003
 
NNPS:  FALSE'
 
Therapeutic Category:  Anti-inflammatory
 
-
-